Sanofi Recalls Mozobil Vials Due to Incorrect or Missing Package Insert
Sanofi-Aventis is recalling 2,133 vials of Mozobil (plerixafor) nationwide because the package insert is incorrect or missing.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The recall is classified as FDA Class III, which indicates the product is not likely to cause adverse health consequences. The issue is limited to packaging documentation.
Plain-English summary
Sanofi-Aventis U.S. LLC is recalling 2,133 vials of Mozobil (plerixafor) injection, 24mg/1.2mL, distributed nationwide. The recall was initiated because the product has an incorrect or missing package insert.
The affected product is identified by Lot numbers 5RZ001C and 5RZ001D, with an expiration date of 04/18. The vials are intended for subcutaneous use and are manufactured by Genzyme Corporation.
Healthcare providers and patients should stop using the affected vials and contact Sanofi-Aventis for further instructions or replacement.
The recalled product
- Product
- MOZOBIL (PLERIXAFOR)
- Brand
- MOZOBIL
- Manufacturer
- Sanofi-Aventis U.S. LLC
- Category
- Drug — Prescription Injection
- Hazard
- Affected units
- 2,133
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot #: 5RZ001C
- 5RZ001D
- Exp. 04/18
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · MOZOBIL
- LowGenzyme Recalls Mozobil Vials Due to Incorrect or Missing Lot and Expiration Dates
FDA (Drugs) · 2016-09-28
Same manufacturer · Sanofi-Aventis U.S. LLC
See all →- HighADMELOG Insulin Lispro Recalled for Malformed Seal Defect
FDA (Drugs) · 2023-05-24
- ModerateSanofi Recalls Elitek (Rasburicase) Vials Due to Stability Testing Failures
FDA (Drugs) · 2020-08-26
- SevereSanofi Recalls Zantac Tablets Due to NDMA Impurity
FDA (Drugs) · 2019-12-11
- SevereSanofi Recalls Regular Strength Zantac 75 mg Due to NDMA Impurity
FDA (Drugs) · 2019-12-11
- SevereSanofi Recalls Zantac 150 mg Tablets Due to NDMA Impurity
FDA (Drugs) · 2019-12-11
Same hazard · mis labeling
See all →- ModerateMedline Trach Tube Kit Recalled for Component Labeling Discrepancy
FDA (Devices) · 2026-09-02
- ModerateAVID Medical Recalls Halyard Total Joint Kits for Latex Labeling Deficiency
FDA (Devices) · 2026-09-02
- ModerateOlympus Recalls PowerSeal Sealer Due to Incorrect Outer Box Labeling
FDA (Devices) · 2026-09-02
- HighSura Tanmen Ramen Noodles Recalled for Undeclared Fish Allergens
FDA (Food) · 2026-09-02
- SevereWhite Vein Advanced Alkaloids Chewable Tablets Recall for Excess Active Ingredient
FDA (Food) · 2026-09-02